Apply to trial NCT06479239

A few quick questions so the study team can decide if you might be a fit.

RecruitingDrug trial

Study of EGFRBi Armed Fresh PBMC in Metastatic or Unresectable Pancreatic Cancer

The purpose of this study is to understand the safety and estimate the efficacy of combining anti-cluster of differentiation 3 (CD3) x anti-Epidermal Growth Factor Receptor (EGFR) bispecific antibody fresh peripheral blood mononuclear cells (EGFR FPBMC) for patients with metastatic or unresectable pancreas cancer. Participants receive 8 twice weekly doses and then 8 more doses every 2 weeks of EGFR FPBMC by intravenous infusion.

How this works

Answer a few questions
About 5 to 10 minutes. Skip-friendly where possible.
We connect you with the study team
When a site picks up your application, we introduce you to their team directly — with you on the thread.
The team reaches out to schedule screening
Usually within a few business days, via the contact you give.

EmailWe save your progress under this email and copy you when we connect you with the study team.

I agree that Hipa.ai may share my application — my name, contact details, and my answers, including health information — with the official study team for this trial so they can review my responses and contact me.

By continuing, you agree to our terms of service.

Study of EGFRBi Armed Fresh PBMC in Metastatic or Unresectable Pancreatic Cancer

How this works

Answer a few questions

We connect you with the study team

The team reaches out to schedule screening